JP2015509110A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509110A5
JP2015509110A5 JP2014555351A JP2014555351A JP2015509110A5 JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5 JP 2014555351 A JP2014555351 A JP 2014555351A JP 2014555351 A JP2014555351 A JP 2014555351A JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5
Authority
JP
Japan
Prior art keywords
tautomer
compound
pharmaceutically acceptable
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555351A
Other languages
English (en)
Japanese (ja)
Other versions
JP6002785B2 (ja
JP2015509110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/050555 external-priority patent/WO2013114250A1/en
Publication of JP2015509110A publication Critical patent/JP2015509110A/ja
Publication of JP2015509110A5 publication Critical patent/JP2015509110A5/ja
Application granted granted Critical
Publication of JP6002785B2 publication Critical patent/JP6002785B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555351A 2012-02-03 2013-01-22 ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体 Expired - Fee Related JP6002785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594460P 2012-02-03 2012-02-03
US61/594,460 2012-02-03
PCT/IB2013/050555 WO2013114250A1 (en) 2012-02-03 2013-01-22 Benziimidazole and imidazopyridine derivatives as sodium channel modulators

Publications (3)

Publication Number Publication Date
JP2015509110A JP2015509110A (ja) 2015-03-26
JP2015509110A5 true JP2015509110A5 (https=) 2016-02-12
JP6002785B2 JP6002785B2 (ja) 2016-10-05

Family

ID=47846092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555351A Expired - Fee Related JP6002785B2 (ja) 2012-02-03 2013-01-22 ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体

Country Status (9)

Country Link
US (1) US8927587B2 (https=)
EP (1) EP2809655B1 (https=)
JP (1) JP6002785B2 (https=)
AR (1) AR089865A1 (https=)
CA (1) CA2861439C (https=)
ES (1) ES2548228T3 (https=)
TW (1) TW201341370A (https=)
UY (1) UY34602A (https=)
WO (1) WO2013114250A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
CA2940897A1 (en) * 2014-02-27 2015-09-03 Epirus Biopharmaceuticals, Inc. Heterocyclic inhibitors of the sodium channel
CA2950393A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
DK3348547T3 (da) * 2015-09-11 2020-09-14 Sumitomo Dainippon Pharma Co Ltd Benzimidazolderivater som nav 1.7 (calciumkanal, spændingsstyret, type ix, alfa undergruppe (scn9a))-inhibitorer til behandling af smerte, dysuria og multipel sclerose
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
CN110621652A (zh) * 2017-05-17 2019-12-27 株式会社德山 二氨基苯化合物的制造方法
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
WO2019138017A1 (en) * 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators
WO2019157505A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
WO2021211408A1 (en) * 2020-04-14 2021-10-21 The Trustees Of The University Of Pennsylvania Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules
WO2022108849A1 (en) * 2020-11-17 2022-05-27 Arisan Therapeutics Inc. Heterocyclic compounds as therapeutic agents
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び(ハロ)アルコキシ置換テトラヒドロフラン
JP2024520646A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのn-(ヒドロキシアルキル(ヘテロ)アリール)テトラヒドロフランカルボキサミド類似体
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
MA64856B1 (fr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CN114249654B (zh) * 2021-12-30 2023-11-14 江苏广域化学有限公司 烷基苯胺类化合物的制备方法
AU2023209523A1 (en) 2022-01-18 2024-08-15 Chengdu Kanghong Pharmaceutical Co., Ltd. Aromatic fused ring nav1.8 inhibitor, and use thereof
CN114288289A (zh) * 2022-02-17 2022-04-08 昆山彭济凯丰生物科技有限公司 具有镇痛和/或止痒功能的药物组合物及其应用
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GEAP202516634A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
IL316433A (en) 2022-04-25 2024-12-01 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of NA v1.8 for the treatment of pain
AU2023391870A1 (en) 2022-12-06 2025-06-05 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
CN116621789A (zh) * 2023-05-31 2023-08-22 上海吉奉生物科技有限公司 一种(4s)-3-[2-[[芴甲氧羰基]氨基]乙酰基]-2,2-二甲基-4-恶唑烷羧酸的合成方法
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8604566D0 (sv) * 1986-10-27 1986-10-27 Haessle Ab Novel compunds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR20030060904A (ko) * 2000-10-06 2003-07-16 뉴로젠 코포레이션 Crf 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
JP2006504660A (ja) * 2002-07-31 2006-02-09 ユーロ−セルティーク エス.エイ. アリール置換ベンゾイミダゾール類およびナトリウムチャネルブロッカーとしてのそれらの使用
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス, インコーポレイテッド p70S6キナーゼモジュレーターおよび使用方法
WO2005113580A1 (en) 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
EP2004613A2 (en) * 2006-03-31 2008-12-24 AstraZeneca AB Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
JP5361857B2 (ja) 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
WO2008135830A1 (en) 2007-05-03 2008-11-13 Pfizer Limited N- [6-amino-s- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
CA2709883A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
US8628695B2 (en) 2008-04-18 2014-01-14 E I Du Pont De Nemours And Company Surface-modified ruthenium oxide conductive material, lead-free glass(es), thick film resistor paste(s), and devices made therefrom
ES2613739T3 (es) * 2008-10-30 2017-05-25 Biogen Ma Inc. Análogos heterobicíclicos de 1-fosfato de esfingosina
JP5667934B2 (ja) * 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規2環性複素環化合物からなる医薬
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL

Similar Documents

Publication Publication Date Title
JP2015509110A5 (https=)
JP2014506907A5 (https=)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2014511891A5 (https=)
JP2014511892A5 (https=)
JP2016514159A5 (https=)
JP2013537203A5 (https=)
JP2019516739A5 (https=)
JP2010524932A5 (https=)
JP2014508811A5 (https=)
JP2014508804A5 (https=)
JP2015516427A5 (https=)
JP2016516043A5 (https=)
JP2015504081A5 (https=)
JP2016506960A5 (https=)
JP2013056919A5 (https=)
JP2014523851A5 (https=)
JP2013508279A5 (https=)
JP2012506896A5 (https=)
JP2016505614A5 (https=)
JP2017517565A5 (https=)
JP2011527299A5 (https=)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
JP2013513607A5 (https=)